Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
General Poster Session

Real-World Data from the MiniMed™ 670G System Commercial Launch

  1. PRATIK AGRAWAL,
  2. MICHAEL STONE,
  3. SHWETA GOPALAKRISHNAN,
  4. CATHERINE FOGEL,
  5. SCOTT W. LEE and
  6. FRANCINE R. KAUFMAN
  1. Northridge, CA
Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-960-P
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

The Medtronic MiniMed™ 670G hybrid closed-loop system with SmartGuard™ technology, which automatically adjusts basal insulin delivery, was released for commercial use in the U.S. in March 2017. Data from the first 13,9patients to use the system are reported.

MiniMed™ 670G data from patients who voluntarily uploaded to CareLink™ Personal software, from 3/17/17 to 12/14/17, were de-identified and analyzed if there were ≥7 days of sensor wear. Comparisons of glycemic metrics between 258,415 patient-days in the initial open-loop Manual Mode and 724,220 patient-days after starting closed-loop Auto Mode were made. Data were compared for patients 7-13 years, 14-21 years, 22-60 years, and ≥60 years.

The Table shows glycemic metrics, including time in target range (TIR, 70-180mg/dL), during Manual Mode and after Auto Mode start for all users and by age group. Children and teens had lower baseline TIR and more hyperglycemia in Manual Mode vs. adults, but a similar magnitude of improvement when in Auto Mode. Older adults had the most optimal glycemia with Auto Mode. TIR was higher in patients with greater time in Auto Mode. For those in Auto Mode 50-59% of the time, mean TIR was 65%; for Auto Mode 60-80% of the time, TIR was 68%; and for Auto Mode >80% of the time, TIR was 74%.

Overall, data from the commercial launch of the MiniMed™ 670G system mirrored the pivotal trial1 results for all ages and showed an increase in TIR with less hypoglycemia and hyperglycemia.

View this table:
  • View inline
  • View popup

Disclosure P. Agrawal: None. M. Stone: None. S. Gopalakrishnan: Employee; Self; Medtronic. C. Fogel: Employee; Self; Medtronic. S.W. Lee: Employee; Self; Medtronic. F.R. Kaufman: Employee; Self; Medtronic.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 67 (Supplement 1)

In this Issue

July 2018, 67(Supplement 1)
  • Table of Contents
  • Index by Author
  • Abstract PDFs
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-World Data from the MiniMed™ 670G System Commercial Launch
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Real-World Data from the MiniMed™ 670G System Commercial Launch
PRATIK AGRAWAL, MICHAEL STONE, SHWETA GOPALAKRISHNAN, CATHERINE FOGEL, SCOTT W. LEE, FRANCINE R. KAUFMAN
Diabetes Jul 2018, 67 (Supplement 1) 960-P; DOI: 10.2337/db18-960-P

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Real-World Data from the MiniMed™ 670G System Commercial Launch
PRATIK AGRAWAL, MICHAEL STONE, SHWETA GOPALAKRISHNAN, CATHERINE FOGEL, SCOTT W. LEE, FRANCINE R. KAUFMAN
Diabetes Jul 2018, 67 (Supplement 1) 960-P; DOI: 10.2337/db18-960-P
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

General Poster Session

  • Glucagon Expression Is Regulated by Exendin-4 via CaMKK/AMPK/FoxO1 Pathway in Alpha TC1.6 Cells
  • Effect of Restricted Caloric Intake and Bariatric Surgery on PCSK9 Concentrations in Plasma
  • Unusual Duct-Like Cells in the Islet of Diabetic C414A-CRY1 Transgenic Mice
Show more General Poster Session

Clinical Diabetes/Therapeutics

  • Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes
  • Care of the Transgender Adolescent with Type 1 Diabetes
  • Diabetes Mellitus Type 1 in Patient with Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency
Show more Clinical Diabetes/Therapeutics

Clinical Therapeutics/New Technology–Insulin Delivery Systems

  • Controlled Release of Insulin Granules from PLGA Microparticles for Glucose Modulation in Diabetes
  • Diabetes Management in Hospitalized Patients with Type 2 Diabetes (T2D) during Fasting Periods
  • A Comparative Study of Hybrid Artificial Pancreas and Virtual Pancreas System
Show more Clinical Therapeutics/New Technology–Insulin Delivery Systems

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.